Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The administration of intravenous crystalloids is ubiquitous in the care of the critically ill. Commonly available crystalloid solutions contain a broad spectrum of electrolyte compositions including a range of chloride concentrations. Recent studies of associated higher fluid chloride content with acute kidney injury and mortality but no large, randomized trials have been conducted. In preparation for a large, cluster-randomized, multiple-crossover trial comparing 0.9% sodium chloride to physiologically-balanced isotonic crystalloids (Lactated Ringers or Plasmalyte-A) in intensive care unit patients, this pilot study will enroll all patients admitted to the medical intensive care unit at a single tertiary center for a sixth month period. The primary objective will be to test the ability of an electronic order entry tool to ensure administration of assigned study fluid or record contraindications to assigned study fluid. The pilot study will also demonstrate the feasibility of collecting demographic, severity of illness, fluid management, vital sign, laboratory, acute kidney injury and renal replacement therapy, and outcome data in an automated, electronic fashion.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 0.9% sodium chloride | Active Comparator | Participants in the '0.9% sodium chloride' arm will receive 0.9% sodium chloride ('normal saline') any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission. |
|
| Physiologically balanced fluid | Active Comparator | Participants in the 'physiologically balanced fluid' arm will receive physiologically balanced fluid (Lactated ringers or Plasmalyte-A) any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 0.9% sodium chloride | Other |
| ||
| Physiologically balanced fluid |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of Isotonic Crystalloid Which is 0.9% Saline | Proportion of total intravenous isotonic crystalloid administered during admission to the intensive care unit that is 0.9% sodium chloride, censored at 30 days. The primary outcome was the proportion of intravenous isotonic crystalloid administered in the ICU that was saline. This was a continuous variable calculated for each patient as the volume of saline received divided by volume of saline received plus volume of balanced crystalloids received with a range from 0.0 (no saline received) to 1.0 (only saline received). | 30 days |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of Isotonic Crystalloid Which is Physiologically Balanced | Proportion of total intravenous isotonic crystalloid administered during admission to the intensive care unit that is either Lactated ringers or Plasmalyte-A, censored at 30 days. | 30 days |
| Total Intravenous Input |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Todd W Rice, M.D., M.Sc. | Vanderbilt University Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Vanderbilt University Medical Center | Nashville | Tennessee | 37209 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 21705897 | Background | Yunos NM, Kim IB, Bellomo R, Bailey M, Ho L, Story D, Gutteridge GA, Hart GK. The biochemical effects of restricting chloride-rich fluids in intensive care. Crit Care Med. 2011 Nov;39(11):2419-24. doi: 10.1097/CCM.0b013e31822571e5. | |
| 23073953 | Background | Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA. 2012 Oct 17;308(15):1566-72. doi: 10.1001/jama.2012.13356. |
Not provided
Not provided
Not provided
This cluster-randomized, multiple-crossover trial enrolled 974 adults admitted to a tertiary medical intensive care unit from February 3, 2015 to May 31, 2015.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | 0.9% Sodium Chloride | Participants in the '0.9% sodium chloride' arm will receive 0.9% sodium chloride ('normal saline') any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission. 0.9% sodium chloride |
| FG001 | Physiologically Balanced Fluid | Participants in the 'physiologically balanced fluid' arm will receive physiologically balanced fluid (Lactated ringers or Plasmalyte-A) any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission. Physiologically balanced fluid |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | 0.9% Sodium Chloride | Participants in the '0.9% sodium chloride' arm will receive 0.9% sodium chloride ('normal saline') any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission. 0.9% sodium chloride |
| BG001 | Physiologically Balanced Fluid |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Proportion of Isotonic Crystalloid Which is 0.9% Saline | Proportion of total intravenous isotonic crystalloid administered during admission to the intensive care unit that is 0.9% sodium chloride, censored at 30 days. The primary outcome was the proportion of intravenous isotonic crystalloid administered in the ICU that was saline. This was a continuous variable calculated for each patient as the volume of saline received divided by volume of saline received plus volume of balanced crystalloids received with a range from 0.0 (no saline received) to 1.0 (only saline received). | Posted | Mean | Full Range | Percentage of fluid that was saline | 30 days |
|
30 days
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | 0.9% Sodium Chloride | Participants in the '0.9% sodium chloride' arm will receive 0.9% sodium chloride ('normal saline') any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission. 0.9% sodium chloride |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Matthew Semler | Vanderbilt University Medical Center | 615-322-3412 | matthew.w.semler@vumc.org |
Not provided
| ID | Term |
|---|---|
| D058186 | Acute Kidney Injury |
| ID | Term |
|---|---|
| D051437 | Renal Insufficiency |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D012965 | Sodium Chloride |
| D000077325 | Ringer's Lactate |
| C048013 | Plasmalyte A |
| ID | Term |
|---|---|
| D002712 | Chlorides |
| D006851 | Hydrochloric Acid |
| D017606 | Chlorine Compounds |
| D007287 | Inorganic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Other |
|
|
Total volume of intravenous fluid administration during admission to the intensive care unit, censored at 30 days |
| 30 days |
| Total Isotonic Crystalloid Input | Total volume of intravenous isotonic crystalloid administration during admission to the intensive care unit, censored at 30 days | 30 days |
| Total Intravenous Colloid Input | Total volume of intravenous colloid administration (excluding blood products) during admission to the intensive care unit, censored at 30 days | 30 days |
| Total Intravenous Blood Product Administration | Total volume of packed red blood cells, platelets, and fresh frozen plasma administered during admission to the intensive care unit, censored at 30 days | 30 days |
| Highest Serum Chloride Between Enrollment and Day 30 | highest serum chloride (mmol/L) during admission to the intensive care unit, censored at 30 days | 30 days |
| Highest Serum Sodium Between Enrollment and Day 30 | Highest serum sodium concentration (mmol/L) during admission to the intensive care unit, censored at 30 days | 30 days |
| Lowest Bicarbonate Concentration Between Enrollment and Day 30 | Lowest serum bicarbonate concentration (mmol/L) during admission to the intensive care unit, censored at 30 days | 30 days |
| Number of Patients With MAKE30 | Incidence of Major Adverse Kidney Events by 30 days -- a composite outcome defined as one or more of the following: death, new use of renal replacement therapy, or persistence of renal dysfunction at hospital discharge or at 30 days (defined as an increase in serum creatinine ≥ 200% from baseline) | 30 days |
| In-hospital Mortality | Death prior to the earlier of hospital discharge or day 30 | 30 days |
| New Use of Renal Replacement Therapy | Receipt of new renal replacement therapy after the first study day, censored at 30 days | 30 days |
| Persistent Renal Dysfunction | Persistence of renal dysfunction at hospital discharge or at 30 days (defined as an increase in serum creatinine ≥ 200% from baseline) | 30 days |
| Number of Contraindications | Number of contraindications to assigned study fluid identified by providers, censored at 30 days | 30 days |
| Incidence of Hyperchloremia | Incidence of hyperchloremia defined as a serum chloride greater than or equal to 110 mmol/L | 30 days |
| Incidence of Severe Hypochloremia | Incidence of severe hypochloremia defined as a serum chloride less than 90mmol/L | 30 days |
| Increase in Serum Creatinine | Increase in serum creatinine during hospitalization, censored at 30 days Change from baseline to highest value, median (IQR), mg/dl | 30 days |
| Incidence of Acute Kidney Injury | Incidence of stage II or III acute kidney injury by Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury criteria, censored at 30 days | 30 days |
| Intensive Care Unit Free Days to Day 28 | ICU-free days to 28 days after enrollment will be defined as the number of days alive and not admitted to an intensive care unit service after the patient's final discharge from the intensive care unit before 28 days. If the patient is admitted to an intensive care unit service at day 28 or dies prior to day 28, ICU-free days will be 0. | 28 days |
| Ventilator-free Days (VFD) to Day 28 | Ventilator-free days to day 28 will be defined as the number of days alive and with unassisted breathing to day 28 after enrollment, assuming a patient survives for at least two consecutive calendar days after initiating unassisted breathing and remains free of assisted breathing. If a patient returns to assisted breathing and subsequently achieves unassisted breathing prior to day 28, VFD will be counted from the end of the last period of assisted breathing to day 28. If the patient is receiving assisted ventilation at day 28 or dies prior to day 28, VFD will be 0. | 28 days |
| Dialysis-free Survival to Day 28 | Dialysis free survival to day 28 will be defined as the number of days alive and without dialysis receipt to day 28 after enrollment, assuming a patient survives for at least two consecutive calendar days after last receipt of dialysis and remains free of dialysis. If the patient is receiving dialysis at day 28 or dies prior to day 28, VFD will be 0. | 28 days |
| Peak Creatinine in the First 30 Days | Highest creatinine value in the first 30 days | 30 days |
| 24674927 | Background | Raghunathan K, Shaw A, Nathanson B, Sturmer T, Brookhart A, Stefan MS, Setoguchi S, Beadles C, Lindenauer PK. Association between the choice of IV crystalloid and in-hospital mortality among critically ill adults with sepsis*. Crit Care Med. 2014 Jul;42(7):1585-91. doi: 10.1097/CCM.0000000000000305. |
| 27749094 | Derived | Semler MW, Wanderer JP, Ehrenfeld JM, Stollings JL, Self WH, Siew ED, Wang L, Byrne DW, Shaw AD, Bernard GR, Rice TW; SALT Investigators * and the Pragmatic Critical Care Research Group; SALT Investigators. Balanced Crystalloids versus Saline in the Intensive Care Unit. The SALT Randomized Trial. Am J Respir Crit Care Med. 2017 May 15;195(10):1362-1372. doi: 10.1164/rccm.201607-1345OC. |
Participants in the 'physiologically balanced fluid' arm will receive physiologically balanced fluid (Lactated ringers or Plasmalyte-A) any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission. Physiologically balanced fluid |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Body mass index | Body mass index, median (IQR), kg/m2 | Median | Inter-Quartile Range | kg/m^2 |
|
| Chronic kidney disease, stage III or greater | Count of Participants | Participants |
|
| Previous renal replacement therapy | Count of Participants | Participants |
|
| Source of ICU Admission | Count of Participants | Participants |
|
| Mechanical ventilation | Count of Participants | Participants |
|
| Vasopressors | Count of Participants | Participants |
|
| Acute kidney injury, stage II or greater | Count of Participants | Participants |
|
| OG001 | Physiologically Balanced Fluid | Participants in the 'physiologically balanced fluid' arm will receive physiologically balanced fluid (Lactated ringers or Plasmalyte-A) any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission. Physiologically balanced fluid |
|
|
|
| Secondary | Proportion of Isotonic Crystalloid Which is Physiologically Balanced | Proportion of total intravenous isotonic crystalloid administered during admission to the intensive care unit that is either Lactated ringers or Plasmalyte-A, censored at 30 days. | Posted | Mean | Full Range | Percentage of fluid that was balanced | 30 days |
|
|
|
| Secondary | Total Intravenous Input | Total volume of intravenous fluid administration during admission to the intensive care unit, censored at 30 days | Posted | Median | Inter-Quartile Range | milliliters | 30 days |
|
|
|
| Secondary | Total Isotonic Crystalloid Input | Total volume of intravenous isotonic crystalloid administration during admission to the intensive care unit, censored at 30 days | Posted | Median | Inter-Quartile Range | mL | 30 days |
|
|
|
| Secondary | Total Intravenous Colloid Input | Total volume of intravenous colloid administration (excluding blood products) during admission to the intensive care unit, censored at 30 days | Posted | Median | Inter-Quartile Range | milliliters | 30 days |
|
|
|
| Secondary | Total Intravenous Blood Product Administration | Total volume of packed red blood cells, platelets, and fresh frozen plasma administered during admission to the intensive care unit, censored at 30 days | Posted | Median | Inter-Quartile Range | milliliters | 30 days |
|
|
|
| Secondary | Highest Serum Chloride Between Enrollment and Day 30 | highest serum chloride (mmol/L) during admission to the intensive care unit, censored at 30 days | Posted | Median | Inter-Quartile Range | mmol/L | 30 days |
|
|
|
| Secondary | Highest Serum Sodium Between Enrollment and Day 30 | Highest serum sodium concentration (mmol/L) during admission to the intensive care unit, censored at 30 days | Posted | Median | Inter-Quartile Range | mmol/L | 30 days |
|
|
|
| Secondary | Lowest Bicarbonate Concentration Between Enrollment and Day 30 | Lowest serum bicarbonate concentration (mmol/L) during admission to the intensive care unit, censored at 30 days | Posted | Median | Inter-Quartile Range | mmol/L | 30 days |
|
|
|
| Secondary | Number of Patients With MAKE30 | Incidence of Major Adverse Kidney Events by 30 days -- a composite outcome defined as one or more of the following: death, new use of renal replacement therapy, or persistence of renal dysfunction at hospital discharge or at 30 days (defined as an increase in serum creatinine ≥ 200% from baseline) | Posted | Count of Participants | Participants | 30 days |
|
|
|
| Secondary | In-hospital Mortality | Death prior to the earlier of hospital discharge or day 30 | Posted | Count of Participants | Participants | 30 days |
|
|
|
| Secondary | New Use of Renal Replacement Therapy | Receipt of new renal replacement therapy after the first study day, censored at 30 days | Posted | Count of Participants | Participants | 30 days |
|
|
|
| Secondary | Persistent Renal Dysfunction | Persistence of renal dysfunction at hospital discharge or at 30 days (defined as an increase in serum creatinine ≥ 200% from baseline) | Posted | Count of Participants | Participants | 30 days |
|
|
|
| Secondary | Number of Contraindications | Number of contraindications to assigned study fluid identified by providers, censored at 30 days | Order for intravenous crystalloid is the unit analyzed; each patient could have multiple orders for intravenous crystalloid | Posted | Count of Units | Orders for intravenous crystalloid | 30 days | Orders for intravenous crystalloid | Orders for intravenous crystalloid |
|
|
|
| Secondary | Incidence of Hyperchloremia | Incidence of hyperchloremia defined as a serum chloride greater than or equal to 110 mmol/L | Posted | Count of Participants | Participants | 30 days |
|
|
|
| Secondary | Incidence of Severe Hypochloremia | Incidence of severe hypochloremia defined as a serum chloride less than 90mmol/L | Posted | Count of Participants | Participants | 30 days |
|
|
|
| Secondary | Increase in Serum Creatinine | Increase in serum creatinine during hospitalization, censored at 30 days Change from baseline to highest value, median (IQR), mg/dl | Posted | Median | Inter-Quartile Range | mg/dL | 30 days |
|
|
|
| Secondary | Incidence of Acute Kidney Injury | Incidence of stage II or III acute kidney injury by Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury criteria, censored at 30 days | Posted | Count of Participants | Participants | 30 days |
|
|
|
| Secondary | Intensive Care Unit Free Days to Day 28 | ICU-free days to 28 days after enrollment will be defined as the number of days alive and not admitted to an intensive care unit service after the patient's final discharge from the intensive care unit before 28 days. If the patient is admitted to an intensive care unit service at day 28 or dies prior to day 28, ICU-free days will be 0. | Posted | Median | Inter-Quartile Range | days | 28 days |
|
|
|
| Secondary | Ventilator-free Days (VFD) to Day 28 | Ventilator-free days to day 28 will be defined as the number of days alive and with unassisted breathing to day 28 after enrollment, assuming a patient survives for at least two consecutive calendar days after initiating unassisted breathing and remains free of assisted breathing. If a patient returns to assisted breathing and subsequently achieves unassisted breathing prior to day 28, VFD will be counted from the end of the last period of assisted breathing to day 28. If the patient is receiving assisted ventilation at day 28 or dies prior to day 28, VFD will be 0. | Posted | Median | Inter-Quartile Range | days | 28 days |
|
|
|
| Secondary | Dialysis-free Survival to Day 28 | Dialysis free survival to day 28 will be defined as the number of days alive and without dialysis receipt to day 28 after enrollment, assuming a patient survives for at least two consecutive calendar days after last receipt of dialysis and remains free of dialysis. If the patient is receiving dialysis at day 28 or dies prior to day 28, VFD will be 0. | Posted | Median | Inter-Quartile Range | days | 28 days |
|
|
|
| Secondary | Peak Creatinine in the First 30 Days | Highest creatinine value in the first 30 days | Posted | Median | Inter-Quartile Range | mg/dL | 30 days |
|
|
|
| 68 |
| 454 |
| 0 |
| 454 |
| 0 |
| 454 |
| EG001 | Physiologically Balanced Fluid | Participants in the 'physiologically balanced fluid' arm will receive physiologically balanced fluid (Lactated ringers or Plasmalyte-A) any time an isotonic crystalloid is ordered by a provider during the intensive care unit admission. Physiologically balanced fluid | 72 | 520 | 0 | 520 | 0 | 520 |
Not provided
Not provided
Not provided
| D005261 |
| Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D017670 |
| Sodium Compounds |
| D000077324 | Crystalloid Solutions |
| D007552 | Isotonic Solutions |
| D012996 | Solutions |
| D004364 | Pharmaceutical Preparations |